by barry101 | Jan 18, 2022 | Press Releases
– Review of preliminary interim data continues to demonstrate the absence of cardiotoxicity for Annamycin, representing a significant advancement in patient safety- Preliminary interim data for Annamycin shows a reduced rate of alopecia compared to currently...
by barry101 | Jan 7, 2022 | Press Releases
HOUSTON, Jan. 7, 2022 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today...
by barry101 | Dec 27, 2021 | Press Releases
– Preliminary data currently demonstrate 50% of patients in first two cohorts experienced clinical activity, defined as stable disease and/or better through 4 months or more of treatment- Patient enrollment and dosing ongoing; no dose-limiting toxicity (DLT)...
by barry101 | Dec 1, 2021 | Press Releases
New US IND enables parallel development of WP1122 as a cancer therapy HOUSTON, Dec. 1, 2021 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly...
by barry101 | Nov 12, 2021 | Press Releases
– Live moderated video webcast discussion among members of management and Thought Leader Sant P. Chawla, MD on Thursday, November 18th at 11:00 AM ET -HOUSTON, Nov. 12, 2021 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical...
by barry101 | Nov 11, 2021 | Press Releases
– Up to six clinical trials expected to be underway or with regulatory clearance by the end of 2021 — Preliminary clinical activity for Annamycin seen in interim results from its US Phase 1b/2 clinical trial for the treatment of soft tissue sarcoma (STS)...
